54 completed, 9 withdrawn, 6 unknown, 4 recruiting. 30 Phase 3, 19 Phase 4, 10 Phase 2, 7 Phase 1, 6 Not applicable.
Follow Chlorthalidone: new trials by email Literature Review of Chlorthalidone trials Research Report on Chlorthalidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cardiac Effects of Mineralocorticoid Receptor Antagonism After Hypertensive Disorders of Pregnancy Eplerenone 100 mg daily, Chlorthalidone 25 mg daily, Potassium Placebo - Hypertension | Phase 2 | Recruiting | Massachusetts General Hospital | 90 | 2026-03-20 | 2026-10-20 |
| CaOx Stone Prevention Chlorthalidone, Low oxalate diet - Kidney Stones | Phase 4 | Recruiting | Icahn School of Medicine at Mount Sinai | 80 | 2025-10-23 | 2026-08-14 |
| Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention Indapamide 2.5 MG, Hydrochlorothiazide 50Mg, Chlorthalidone 25mg - Kidney Stone | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 99 | 2024-10-01 | 2026-05-06 |
| Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension. chlorthalidone, Placebo - Essential Hypertension, Older Adults | Early Phase 1 | Completed | University of Texas Southwestern Medical Center | 27 | 2024-08-15 | 2026-02-27 |
| Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg - Essential Hypertension | Phase 4 | Active not recruiting | Yuhan Corporation | 198 | 2023-10-18 | 2026-02-13 |
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension Eplerenone, Chlorthalidone, Potassium - Hypertension, Left Ventricular Hypertrophy | Phase 4 | Recruiting | Brigham and Women's Hospital | 75 | 2023-08-25 | 2026-04-06 |
| Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension candesartan cilexetil + chlorthalidone + amlodipine, Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) - Hypertension | Phase 3 | Completed | Hospital Israelita Albert Einstein | 702 | 2023-08-22 | 2025-07-09 |
| Skin Sodium and Salt Sensitivity of Blood Pressure Amlodipine, Chlortalidone - Hypertension | Not applicable | Unknown | Cambridge University Hospitals NHS Foundation Trust | 60 | 2023-08-01 | 2023-08-04 |
| Diuretic Use in Hemodialysis Patients With Residual Renal Function Furosemide, Chlorthalidone - End Stage Renal Disease on Dialysis | Phase 4 | Terminated | University of Alberta | 2 | 2023-05-29 | 2026-05-08 |
| Diuretics and Volume Overload in Early CKD Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) - Chronic Kidney Disease, Hypertension | Phase 4 | Completed | VA Office of Research and Development | 49 | 2023-02-01 | 2026-09-21 |
| Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN) Amlodipine Besylate, Chlorthalidone - High Blood Pressure, Liver Transplant | Phase 4 | Withdrawn | Northwestern University | 2022-07-12 | 2023-10-13 | |
| Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension Losartan/Chlorthalidone in fixed dose, Losartan + hydrochlorothiazide in fixed dose - Essential Arterial Hypertension | Phase 3 | Completed | Laboratorios Silanes S.A. de C.V. | 163 | 2022-06-30 | 2025-03-13 |
| Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment UNa measurement after intravenous loop diuretic bolus, Intravenous acetazolamide 500 mg OD, Intravenous bumetanide TID - Acute Heart Failure, Diuretics Drug Reactions | Phase 4 | Completed | Vrije Universiteit Brussel | 107 | 2022-06-12 | 2026-09-11 |
| Spironolactone in CKD Enabled by Chlorthalidone: PILOT Spironolactone, Chlorthalidone, Placebo - Renal Insufficiency, Chronic Hypertension | Phase 2 | Unknown | Indiana Institute for Medical Research | 24 | 2022-02-01 | 2023-08-14 |
| Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers. Bupropion, Anastrozole, Testosterone cyclopentylpropionate - Healthy Volunteers | Phase 1 | Completed | Parc de Salut Mar | 9 | 2020-12-03 | 2021-04-26 |
| Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity Eplerenone, Chlorthalidone with potassium chloride - Metabolic Syndrome, Hypertension | Phase 4 | Completed | Brigham and Women's Hospital | 79 | 2020-12-01 | 2026-09-15 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension. Chlorthalidone 25 mg, Hydrochlorothiazide 50 mg, Amiloride 20 mg - Hypertension | Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 84 | 2019-11-13 | 2019-12-09 |
| Safety and Efficacy of Chlorthalidone in Type 1 Diabetes Chlorthalidone - Type 1 Diabetes Mellitus, Hypercalciuria | Phase 2 | Terminated | University of Rochester | 1 | 2019-06-28 | 2021-01-05 |
Showing 20 of 78. Sign in to see all of them.
Hypertension (57) · Cardiovascular Diseases (17) · Essential Hypertension (9) · Heart Diseases (9) · Vascular Diseases (8) · Renal Insufficiency, Chronic (6) · Coronary Disease (3) · Diabetes Mellitus (3) · Kidney Calculi (3) · Nephrolithiasis (3) · Cardio-Renal Syndrome (2) · Edema (2) · Hypercalciuria (2) · Hypercholesterolemia (2) · Kidney Diseases (2)
Takeda (7) · Hospital de Clinicas de Porto Alegre (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Yuhan Corporation (5) · EMS (4) · Hanmi Pharmaceutical Company Limited (3) · Brigham and Women's Hospital (2) · Cambridge University Hospitals NHS Foundation Trust (2) · Creighton University (2) · Indiana University (2) · Laboratorios Silanes S.A. de C.V. (2) · University of Florida (2) · University of Texas Southwestern Medical Center (2) · VA Office of Research and Development (2) · AHEPA University Hospital (1)
United States (32) · South Korea (10) · Brazil (7) · Mexico (6) · United Kingdom (4) · Canada (3) · Netherlands (3) · Puerto Rico (3) · Chile (2) · Germany (2) · Poland (2) · Russia (2) · Switzerland (2) · Austria (1) · Belgium (1)
Ian Wilkinson (2) · Rajiv Agarwal, MD (2) · Sandra C Fuchs, MD, PhD (2) · Adam P Bress, PharmD, MS (1) · Adriana C Forti (1) · Ahmed Aboeata, MBBCh (1) · Albert Oberman (1) · Alp Ikizler, MD (1) · Ana M Aldea Perona, MD PhD (1) · Anand Vaidya, MD (1) · Anthony J Viera, MD, MPH (1)
PMID 41903707, PMID 22470539, PMID 39082471, PMID 11904577, PMID 16651474, PMID 17846352, PMID 18000186, PMID 18227370, PMID 18539917, PMID 18676075, PMID 19001024, PMID 19898642, PMID 19926008, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 21366473, PMID 21663644, PMID 21849262, PMID 21958949, PMID 21969009, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22235820, PMID 22374637, PMID 22396585, PMID 22431578, PMID 22432114, PMID 22450889, PMID 22490878, PMID 22515638, PMID 22619083, PMID 22646230, PMID 22710649, PMID 22723577, PMID 22939358, PMID 23033246, PMID 23194494, PMID 23238658, PMID 23412077, PMID 23529173, PMID 23990163, PMID 24170759
2008 (2), 1IK2CX002368-01A1 (1), K23DK114477 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), P20RR011104 (1), R01HL030171 (1), R01HL034767 (1), R01HL036821 (1), R01HL063082 (1)